Posaconazole

被引：3

作者：

Bhattacharya, M. ^{[1
,3
]}

Rajeshwari, K. ^{[1
,3
]}

Dhingra, B. ^{[2
]}

机构：

[1] Maulana Azad Med Coll, Dept Pediat, New Delhi, India

[2] All India Inst Med Sci, Dept Hematol & Oncol, Delhi, India

[3] Lok Nayak Hosp, New Delhi, India

来源：

JOURNAL OF POSTGRADUATE MEDICINE | 2010年 / 56卷 / 02期

关键词：

Posaconazole; invasive fungal infections; candidiasis; immunocompromised; IN-VITRO ACTIVITIES; AZOLE-REFRACTORY OROPHARYNGEAL; INVASIVE ASPERGILLOSIS; AMPHOTERICIN-B; ESOPHAGEAL CANDIDIASIS; ANTIFUNGAL AGENTS; SALVAGE TREATMENT; SCH; 56592; TRIAZOLE; FLUCONAZOLE;

D O I：

10.4103/0022-3859.65281

中图分类号：

R5 [内科学];

学科分类号：

1002 ; 100201 ;

摘要：

Posaconazole is a novel second-generation Triazole oral antifungal agent. It is highly effective in the prophylaxis of invasive fungal infections in immunocompromised patients. It is used as a first-line agent as well as for salvage therapy in invasive fungal infections including aspergillosis, oropharyngeal and esophageal candidiasis. It has a good adverse effect profile. With the rising incidence of invasive fungal infections due to the HIV pandemic and medical advancements in transplantation and cancer therapy, these features make posaconazole a valuable addition in the family of antifungal agents.

引用

页码：106 / 110

页数：5

共 38 条

[1] Omeprazole Significantly Reduces Posaconazole Serum Trough Level [J].

Alffenaar, Jan-Willem C. ;

van Assen, Sander ;

van der Werf, Tjip S. ;

Kosterink, Jos G. W. ;

Uges, Donald R. A. .

CLINICAL INFECTIOUS DISEASES, 2009, 48 (06) :839-839

[2] Refractory coccidioidomycosis treated with posaconazole [J].

Anstead, GM ;

Corcoran, G ;

Lewis, J ;

Berg, D ;

Graybill, JR .

CLINICAL INFECTIOUS DISEASES, 2005, 40 (12) :1770-1776

[3] Candidemia in a tertiary care cancer center - In vitro susceptibility and its association with outcome of initial antifungal therapy [J].

Antoniadou, A ;

Torres, HA ;

Lewis, RE ;

Thornby, J ;

Bodey, GP ;

Tarrand, JJ ;

Han, XY ;

Rolston, KVI ;

Safdar, A ;

Raad, II ;

Kontoyiannis, DP .

MEDICINE, 2003, 82 (05) :309-321

[4] In vitro activities of the new antifungal triazole SCH 56592 against common and emerging yeast pathogens [J].

Barchiesi, F ;

Arzeni, D ;

Fothergill, AW ;

Di Francesco, LF ;

Caselli, F ;

Rinaldi, MG ;

Scalise, G .

ANTIMICROBIAL AGENTS AND CHEMOTHERAPY, 2000, 44 (01) :226-229

[5] Newer systemic antifungal agents - Pharmacokinetics, safety and efficacy [J].

Boucher, HW ;

Groll, AH ;

Chiou, CC ;

Walsh, TJ .

DRUGS, 2004, 64 (18) :1997-2020

[6]

CLARK B, 2005, J INFECTION, V51, P177

[7] Posaconazole vs. fluconazole or itraconazole prophylaxis in patients with neutropenia [J].

Cornely, Oliver A. ;

Maertens, Johan ;

Winston, Drew J. ;

Perfect, John ;

Ullmann, Andrew J. ;

Walsh, Thomas J. ;

Helfgott, David ;

Holowiecki, Jerzy ;

Stockelberg, Dick ;

Goh, Yeow-Tee ;

Petrini, Mario ;

Hardalo, Cathy ;

Suresh, Ramachandran ;

Angulo-Gonzalez, David .

NEW ENGLAND JOURNAL OF MEDICINE, 2007, 356 (04) :348-359

[8] Effect of food on the relative bioavailability of two oral formulations of posaconazole in healthy adults [J].

Courtney, R ;

Wexler, D ;

Radwanski, E ;

Lim, J ;

Laughlin, M .

BRITISH JOURNAL OF CLINICAL PHARMACOLOGY, 2004, 57 (02) :218-222

[9] Pharmacokinetics, safety, and tolerability of oral posaconazole administered in single and multiple doses in healthy adults [J].

Courtney, R ;

Pai, S ;

Laughlin, M ;

Lim, J ;

Batra, V .

ANTIMICROBIAL AGENTS AND CHEMOTHERAPY, 2003, 47 (09) :2788-2795

[10] Echinocandin antifungal drugs [J].

Denning, DW .

LANCET, 2003, 362 (9390) :1142-1151

← 1 2 3 4 →